Walgreens Boots Alliance, Inc. vs Axsome Therapeutics, Inc.: SG&A Expense Trends

SG&A Expense Trends: Walgreens Boots Alliance vs. Axsome Therapeutics

In the ever-evolving landscape of the pharmaceutical and healthcare industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Walgreens Boots Alliance, Inc. and Axsome Therapeutics, Inc. from 2014 to 2023.

Walgreens Boots Alliance, a global leader in retail pharmacy, consistently reported SG&A expenses exceeding $17 billion annually, peaking at approximately $28 billion in 2024. This reflects their expansive operational scale and strategic investments in customer service and infrastructure.

Conversely, Axsome Therapeutics, a burgeoning biopharmaceutical company, exhibited a dramatic increase in SG&A expenses, skyrocketing from $1.4 million in 2014 to over $323 million in 2023. This 230-fold increase underscores their aggressive growth strategy and market expansion efforts.

While Walgreens' expenses highlight stability and maturity, Axsome's trajectory signals rapid growth and potential market disruption. Missing data for 2024 suggests ongoing developments worth monitoring.